Efficacy of everolimus with exemestane versus exemestane alone in Asian patients with HER2-negative, hormone-receptor-positive breast cancer in BOLERO-2.
about
Everolimus in the Treatment of Metastatic Breast CancerEverolimus plus exemestane for the treatment of advanced breast cancer: a review of subanalyses from BOLERO-2Luminal breast cancer cell lines overexpressing ZNF703 are resistant to tamoxifen through activation of Akt/mTOR signalingEfficacy and safety of everolimus in Chinese metastatic HR positive, HER2 negative breast cancer patients: a real-world retrospective study.Mammalian target of rapamycin (mTOR) inhibitors and combined chemotherapy in breast cancer: a meta-analysis of randomized controlled trialsEverolimus plus exemestane versus bevacizumab-based chemotherapy for second-line treatment of hormone receptor-positive metastatic breast cancer in Greece: An economic evaluation study.Everolimus downregulates estrogen receptor and induces autophagy in aromatase inhibitor-resistant breast cancer cells.Clinical features and risk factors of panitumumab-induced interstitial lung disease: a postmarketing all-case surveillance studyCombined treatment with everolimus and fulvestrant reversed anti-HER2 resistance in a patient with refractory advanced breast cancer: a case report.Endocrine resistance in breast cancer: focus on the phosphatidylinositol 3-kinase/akt/mammalian target of rapamycin signaling pathway.Everolimus plus exemestane as first-line therapy in HR⁺, HER2⁻ advanced breast cancer in BOLERO-2.Impact of patient ethnicity on the metabolic and immunologic effects of PI3K-mTOR pathway inhibition in patients with solid tumor malignancies.Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2.Efficacy and safety of everolimus in combination with trastuzumab and paclitaxel in Asian patients with HER2+ advanced breast cancer in BOLERO-1.Everolimus in combination with exemestane: a review of its use in the treatment of patients with postmenopausal hormone receptor-positive, HER2-negative advanced breast cancer.mTOR inhibitor-induced interstitial lung disease in cancer patients: Comprehensive review and a practical management algorithm.The Promoting Effect of Radiation on Glucose Metabolism in Breast Cancer Cells under the Treatment of Cobalt Chloride.The therapeutic potential of mTOR inhibitors in breast cancer.Risk of mTOR inhibitors induced severe pneumonitis in cancer patients: a meta-analysis of randomized controlled trials.MicroRNA-143 inhibits cell growth by targeting ERK5 and MAP3K7 in breast cancer.Fasting glucose and body mass index as predictors of activity in breast cancer patients treated with everolimus-exemestane: The EverExt studyDifferences Are Important: Breast Cancer Therapy in Different Ethnic GroupsCommunity pharmacist-led telephone follow-up enabled close management of everolimus-induced adverse events in an outpatient with metastatic breast cancer.Genetic polymorphisms associated with adverse reactions of molecular-targeted therapies in renal cell carcinoma.Systematic Literature Review of the Impact of Endocrine Monotherapy and in Combination with Targeted Therapy on Quality of Life of Postmenopausal Women with HR+/HER2- Advanced Breast Cancer.Evaluation of oral care to prevent oral mucositis in estrogen receptor-positive metastatic breast cancer patients treated with everolimus (Oral Care-BC): randomized controlled phase III trial.Managing postmenopausal women with hormone receptor-positive advanced breast cancer who progress on endocrine therapies with inhibitors of the PI3K pathway.
P2860
Q26784920-10DB3684-1CCB-41BB-A3D4-D0ACCC2C392EQ28085004-246D3363-A25B-4284-BAB0-CCB8D2362DCBQ31132241-124AF066-C1EE-4D2B-9AF1-9CDAD54C1312Q33441090-D16C699E-4004-4023-AC2E-EC05187028E7Q34547982-09432791-0E29-4BD5-AC00-C5470A856507Q35736115-4263A110-1D32-4995-AF79-21C197E592AAQ36078905-9AE8ABEE-AD90-4A7C-897F-DFAA683AD145Q36337416-8D053F7D-0A83-489B-BC02-54CFC8464FACQ37074917-CB741542-027C-40FC-8CEC-BE9239C359A7Q37255106-5A176A2A-652C-43D5-AE23-123251324322Q37534910-FE294A22-0ABF-4059-8871-34670469FE9EQ37600837-392FF326-C521-4708-AEAA-10C74E6BA62BQ37671961-2E6B142D-8BFF-41BE-BBF9-8021E52747D8Q37748071-6DF97C22-324E-413E-A405-CEA16A5CDDF6Q38093128-EB7FA53A-6594-4BC0-BE22-6EADB7B5D130Q38603164-BF131E9B-F51E-45F8-9473-FE66528ECADCQ38762365-61B5463F-A598-45E8-BD1C-7AE18F85BE27Q38802412-D4356B42-F25E-42EF-AAC1-394CCB0988E4Q38882776-1FF89FBA-C6AA-4CCB-B556-B0A4842126CCQ41078931-AF19C8A0-C90C-412C-BCD3-EFB2F545779DQ41630845-49A82BF6-7005-4C27-BE3B-5EA570AA25D0Q42346622-3BA01E95-CBDB-45AC-B385-0316E151D03FQ47107266-367D8DF3-E5C2-4488-AF5B-186076927C28Q48306032-DBC553EF-03BE-45EB-B3A4-BCAE3559B9CCQ49970203-2449F03C-2D11-4169-9074-A6276290AB38Q51670690-71DE276C-F756-4E54-A92C-0BCC17C01C91Q54349937-2337F2D3-E931-41CD-BE17-A1331089ED73
P2860
Efficacy of everolimus with exemestane versus exemestane alone in Asian patients with HER2-negative, hormone-receptor-positive breast cancer in BOLERO-2.
description
2013 nî lūn-bûn
@nan
2013 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Efficacy of everolimus with ex ...... ive breast cancer in BOLERO-2.
@ast
Efficacy of everolimus with ex ...... ive breast cancer in BOLERO-2.
@en
Efficacy of everolimus with ex ...... ive breast cancer in BOLERO-2.
@nl
type
label
Efficacy of everolimus with ex ...... ive breast cancer in BOLERO-2.
@ast
Efficacy of everolimus with ex ...... ive breast cancer in BOLERO-2.
@en
Efficacy of everolimus with ex ...... ive breast cancer in BOLERO-2.
@nl
prefLabel
Efficacy of everolimus with ex ...... ive breast cancer in BOLERO-2.
@ast
Efficacy of everolimus with ex ...... ive breast cancer in BOLERO-2.
@en
Efficacy of everolimus with ex ...... ive breast cancer in BOLERO-2.
@nl
P2093
P2860
P1433
P1476
Efficacy of everolimus with ex ...... tive breast cancer in BOLERO-2
@en
P2093
Ashok Panneerselvam
Hideo Inaji
Hirofumi Mukai
Hiroji Iwata
Hirotaka Iwase
Jun Horiguchi
Katsumasa Kuroi
Mona El-Hashimy
Norikazu Masuda
Puttisak Puttawibul
P2860
P2888
P304
P356
10.1007/S12282-013-0444-8
P577
2013-02-13T00:00:00Z
P5875
P6179
1018435401